201 related articles for article (PubMed ID: 33878322)
1. Evaluating the Impact of Physiological Properties of the Gastrointestinal Tract On Drug In Vivo Performance Using Physiologically Based Biopharmaceutics Modeling and Virtual Clinical Trials.
Jereb R; Opara J; Bajc A; Petek B
J Pharm Sci; 2021 Aug; 110(8):3069-3081. PubMed ID: 33878322
[TBL] [Abstract][Full Text] [Related]
2. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
Beloica S; Cvijić S; Bogataj M; Parojčić J
Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutic
Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
[TBL] [Abstract][Full Text] [Related]
5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
6. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
8. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
9. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
Kambayashi A; Dressman JB
J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
[TBL] [Abstract][Full Text] [Related]
10. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
11. Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
Caleffi-Marchesini ER; Herling AA; Macente J; Bonan RH; de Freitas Lima P; Moreno R; Alexandre V; Charbe NB; Borghi-Pangoni FB; Cristofoletti R; Diniz A
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):208-221. PubMed ID: 37916262
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
Loisios-Konstantinidis I; Dressman J
Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
[TBL] [Abstract][Full Text] [Related]
13. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
Aishwarya R; Murthy A; Ahmed T; Chachad S
J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
[TBL] [Abstract][Full Text] [Related]
14. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
[TBL] [Abstract][Full Text] [Related]
15. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
17. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
18. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
[TBL] [Abstract][Full Text] [Related]
20. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
